One of the major goals of the translational research movement has been to bridge the gap from bench to bedside and any initiative to blend the LIS with the LIMS can be understood as an extension of this quest. The lesson from all of this is obvious. We now need to make an effort to understand the relative strengths of LIS and LIMS and proceed to develop new systems that capture the best features of each of them.”
Bruce Friedman, M.D., Professor Emeritus, University of Michigan School of Medicine, Department of Pathology
There’s a lot of discussion about the need for a ‘convergence’ of technologies in the clinical diagnostics sector. Because translational and personalized medicine are built on information derived from genetic and molecular diagnostics, accessing this information has proved to be a catalyst in the convergence of technologies that support a traditionally patient-centric environment, like a hospital or clinic, and the more sample-centric environment traditionally associated with research or diagnostics laboratories. Ultimately what is needed is a streamlined flow of information following the patient from the point of care to molecular testing and results analysis, to diagnoses and treatment. Access to this end-to-end information stream gives the physician more opportunities to diagnose and take advantage of the latest medical advancements.
Several good articles recently published give an overview of the challenges and some of the solutions available. Take a look at this discussion featuring several industry experts, Meeting the Challenges of LIS & Data Mining, published in Clinical Lab Products.
Like what you are learning?
There’s also a slide show link on page 10 of this article that highlights at least one solution to these challenges, featuring the Thermo Scientific Clinical LIMS, which is designed to bridge the gap between the hospital setting and the laboratory, enabling physicians to have lab results and diagnostic information at the patient’s bedside.
A good case study on the work being done by Cambridge-based Foundation Medicine is outlined by Trish Meek, director of product strategy for life sciences at Thermo Fisher Scientific.
Read Breakthrough Personalized Cancer Care Technology for an in-depth understanding of how a clinical LIMS can combine the research-centered functionality of a traditional LIMS with the patient-centered data and capabilities typically found in an LIS. And if you’d like more information about this lab-centric solution that delivers patient-centric results, visit Clinical LIMS resources.
Your comments are welcome and most appreciated.